QTTB logo

Q32 BIO INC

QTTBNASDAQ
πŸ† #3313 by market capUS Equity
$8.36β€”
Last available close Β· quote unavailable
πŸ””
Track QTTB
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 4.3%
14dβ–Ό 9.7%
30dβ–Ό 3.1%
ytdβ–² 154.9%
1yβ–² 315.9%
🏦Market Cap
$250M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
99.8%
High
πŸ’΅FCF Margin
-37.3%
Thin
βš–οΈP/S Ratio
4.6x
Fair
Otter Score
64
Fair

Trading Snapshot

Day Range
β€”
52-Week Range
$1.98 – $23.57
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
29.9M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$54M
Last Q Revenue
β€”
P/E Ratio
2.7
P/S Ratio
4.6x
EPS (TTM)
$0.95
Dividend Yield
0.00%
Dilution (1yr)
+21.5%
QTTB logo

Q32 BIO INC

QTTB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$54M
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$17Mβ–Ό βˆ’125.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$34Mβ–Ό βˆ’50.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
13.2Mβ–² +21.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$33Mβ–Ό βˆ’$26M YoY
StockOtter Β· stockotter.space

About Q32 BIO INC

Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100
Analyst data unavailable.

Latest News & Updates

News unavailable.